Patents Assigned to APEXIGEN, INC.
  • Anti-CD40 antibodies and methods of use
    Patent number: 12606632
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: March 13, 2023
    Date of Patent: April 21, 2026
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • BIOMARKERS FOR CD40 AGONIST THERAPY
    Publication number: 20240336693
    Abstract: Provided are biomarkers and other characteristics for predicting tumor responsiveness to CD40 agonist therapy in certain cancers, including melanoma, PD-L1 negative melanoma, and PD-1 refractory melanoma. Further provided are methods of using these biomarkers and characteristics to identify individuals having cancer for treatment with a CD40 agonist therapy, and subsequently treating these individuals with a CD40 agonist therapy, and related kits and compositions.
    Type: Application
    Filed: August 9, 2022
    Publication date: October 10, 2024
    Applicant: Apexigen, Inc.
    Inventors: Xiaodong Yang, Yuliya Katlinskaya, Erin L. Filbert
  • Anti-PD-L1 antibodies and methods of use
    Patent number: 11078283
    Abstract: Provided are anti-programmed death-ligand 1 (PD-L1) monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and oncological diseases. Specifically, high affinity, humanized anti-PD-L1 antibodies are provided.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: August 3, 2021
    Assignee: Apexigen, Inc.
    Inventors: Pia Björck, Christine Tan, Erin Filbert, Xiaodong Yang
  • Anti-CD40 antibodies
    Patent number: 11001637
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 11, 2021
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Anti-RANKL antibodies and methods of use
    Patent number: 10259878
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 16, 2019
    Assignee: APEXIGEN, INC.
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • Anti-CD40 antibodies
    Patent number: 9994640
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: June 12, 2018
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Anti-IL-6 receptor antibodies and methods of use
    Patent number: 9951136
    Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: April 24, 2018
    Assignee: APEXIGEN, INC.
    Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
  • Anti-CD40 antibodies and methods of use
    Patent number: 9676861
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 13, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Anti-CD40 antibodies
    Patent number: 9556278
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 31, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Anti-KDR antibodies and methods of use
    Patent number: 9441042
    Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: September 13, 2016
    Assignee: Apexigen, Inc.
    Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Methods of inhibiting proliferation of CD40-expressing cancer cells with anti-CD40 antibodies
    Patent number: 9266956
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: February 23, 2016
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Anti-IL-1? antibodies
    Patent number: 9085621
    Abstract: The present invention provides anti-IL-1? monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: July 21, 2015
    Assignee: Apexigen, Inc.
    Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang
  • Polynucleotides encoding anti-CD40 antibodies
    Patent number: 8957193
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: February 17, 2015
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • ANTI-KDR ANTIBODIES AND METHODS OF USE
    Publication number: 20140377282
    Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.
    Type: Application
    Filed: November 1, 2012
    Publication date: December 25, 2014
    Applicant: APEXIGEN, INC.
    Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • ANTI-CD40 ANTIBODIES AND METHODS OF USE
    Publication number: 20140349395
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: June 5, 2014
    Publication date: November 27, 2014
    Applicant: Apexigen, Inc.
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • ANTI-IL-6 RECEPTOR ANTIBODIES AND METHODS OF USE
    Publication number: 20140322239
    Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Application
    Filed: May 2, 2014
    Publication date: October 30, 2014
    Applicant: APEXIGEN, INC.
    Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
  • Anti-CD40 antibodies
    Patent number: 8778345
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: July 15, 2014
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Anti-IL-6 receptor antibodies and methods of use
    Patent number: 8753634
    Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: June 17, 2014
    Assignee: Apexigen, Inc.
    Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
  • ANTI-CD40 ANTIBODIES AND METHODS OF USE
    Publication number: 20140120103
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: October 30, 2013
    Publication date: May 1, 2014
    Applicant: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • ANTI-IL-1BETA ANTIBODIES AND METHODS OF USE
    Publication number: 20130330355
    Abstract: The present invention provides anti-IL-1? monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.
    Type: Application
    Filed: September 9, 2011
    Publication date: December 12, 2013
    Applicant: APEXIGEN, INC.
    Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang